Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma - Report - MDSpire
Advertisement
Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma
Clinical Report: Overlap Syndrome of Myocarditis, Myositis, and Myasthenia Gravis
Overview
This case study presents a 77-year-old woman who developed immune checkpoint inhibitor-associated overlap syndrome of myocarditis, myositis, and myasthenia gravis after anti-PD1 therapy for urothelial carcinoma. The patient was successfully treated with high-dose glucocorticoids, mycophenolate mofetil, and intravenous immunoglobulin, highlighting the importance of early recognition and treatment of this severe immune-related adverse event.
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can lead to severe immune-related adverse events (irAEs) such as myocarditis, myositis, and myasthenia gravis, collectively termed IM3OS. This overlap syndrome poses significant diagnostic and therapeutic challenges, as symptoms can progress rapidly and lead to high morbidity and mortality. Understanding the immunological mechanisms underlying IM3OS is crucial for improving patient outcomes.
Data Highlights
No numerical data or trial data were provided in the article.
Key Findings
IM3OS is a rare but severe irAE associated with immune checkpoint inhibitors.
The patient presented with weakness, ptosis, and dysarthria, indicative of myositis and myasthenia gravis.
Flow cytometry revealed an expansion of memory CD8+ T-cells during disease flare.
A differentiated CD27- CD28- effector memory CD4+ subset was associated with clinical disease activity.
Treatment with glucocorticoids and immunomodulatory therapy led to resolution of symptoms.
Clinical Implications
Healthcare professionals should maintain a high index of suspicion for IM3OS in patients receiving ICIs, particularly when they present with neurological or muscular symptoms. Early intervention with immunosuppressive therapy can significantly improve outcomes and reduce the risk of severe complications.
Conclusion
This case underscores the need for awareness and prompt management of IM3OS in patients treated with immune checkpoint inhibitors, as timely treatment can lead to favorable clinical outcomes.
